(VIRP) Virbac - Ratings and Ratios
Vaccines, Antibiotics, Parasiticides, Dermatology, Petfood
Dividends
| Dividend Yield | 0.45% |
| Yield on Cost 5y | 0.72% |
| Yield CAGR 5y | 17.92% |
| Payout Consistency | 82.1% |
| Payout Ratio | 9.1% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 28.7% |
| Value at Risk 5%th | 40.7% |
| Relative Tail Risk | -13.90% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.45 |
| Alpha | 8.53 |
| CAGR/Max DD | 0.29 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.548 |
| Beta | 0.052 |
| Beta Downside | -0.023 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.85% |
| Mean DD | 11.77% |
| Median DD | 10.63% |
Description: VIRP Virbac January 12, 2026
Virbac SA (ticker VIRP) is a French-based, globally diversified animal-health company that develops, manufactures, and markets pharmaceuticals, vaccines, parasiticides, anti-inflammatory drugs, and ancillary products such as dermatology, dental, diagnostic, nutrition, and pet-food solutions for companion and farm animals. Its customer base spans veterinarians, livestock producers, and pet owners across Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific.
As of FY 2023, Virbac reported €3.3 billion in revenue, up roughly 4 % year-over-year, driven primarily by strong growth in its companion-animal segment (≈ 7 % CAGR over the past three years) and a modest rebound in farm-animal sales after pandemic-related supply constraints. Key economic drivers include rising pet-ownership rates in emerging markets, increased discretionary spending on pet health in mature economies, and a global trend toward antimicrobial-resistance-compliant veterinary antibiotics, which pressures pricing but creates opportunities for premium, stewardship-aligned products. Currency exposure remains a material risk, with roughly 55 % of sales denominated in euros and the remainder spread across USD, RMB, and emerging-market currencies.
For a deeper quantitative breakdown of VIRP’s valuation metrics and scenario analysis, the ValueRay research hub provides a concise, data-first overview.
Piotroski VR‑10 (Strict, 0-10) 9.5
| Net Income (274.0m TTM) > 0 and > 6% of Revenue (6% = 166.3m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 4.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.85% (prev 35.92%; Δ -21.07pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.18 (>3.0%) and CFO 327.0m > Net Income 274.0m (YES >=105%, WARN >=100%) |
| Net Debt (197.0m) to EBITDA (505.9m) ratio: 0.39 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (8.38m) change vs 12m ago -0.93% (target <= -2.0% for YES) |
| Gross Margin 66.56% (prev 33.87%; Δ 32.69pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 171.3% (prev 85.19%; Δ 86.13pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 19.25 (EBITDA TTM 505.9m / Interest Expense TTM 21.1m) >= 6 (WARN >= 3) |
Altman Z'' 4.81
| (A) 0.23 = (Total Current Assets 842.2m - Total Current Liabilities 430.5m) / Total Assets 1.82b |
| (B) 0.05 = Retained Earnings (Balance) 82.4m / Total Assets 1.82b |
| (C) 0.25 = EBIT TTM 406.6m / Avg Total Assets 1.62b |
| (D) 1.41 = Book Value of Equity 1.06b / Total Liabilities 750.3m |
| Total Rating: 4.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 85.49
| 1. Piotroski 9.50pt |
| 2. FCF Yield 5.87% |
| 3. FCF Margin 6.79% |
| 4. Debt/Equity 0.31 |
| 5. Debt/Ebitda 0.39 |
| 6. ROIC - WACC (= 15.90)% |
| 7. RoE 27.38% |
| 8. Rev. Trend 95.88% |
| 9. EPS Trend -9.13% |
What is the price of VIRP shares?
Over the past week, the price has changed by -0.14%, over one month by +5.75%, over three months by +13.99% and over the past year by +14.69%.
Is VIRP a buy, sell or hold?
What are the forecasts/targets for the VIRP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 403.2 | 12.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 371.8 | 3.7% |
VIRP Fundamental Data Overview January 06, 2026
P/E Trailing = 22.6213
P/E Forward = 17.6678
P/S = 2.0992
P/B = 2.7806
Beta = 0.891
Revenue TTM = 2.77b EUR
EBIT TTM = 406.6m EUR
EBITDA TTM = 505.9m EUR
Long Term Debt = 203.9m EUR (from longTermDebt, last quarter)
Short Term Debt = 97.5m EUR (from shortTermDebt, last quarter)
Debt = 325.6m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 197.0m EUR (from netDebt column, last quarter)
Enterprise Value = 3.20b EUR (3.01b + Debt 325.6m - CCE 128.7m)
Interest Coverage Ratio = 19.25 (Ebit TTM 406.6m / Interest Expense TTM 21.1m)
EV/FCF = 17.03x (Enterprise Value 3.20b / FCF TTM 188.2m)
FCF Yield = 5.87% (FCF TTM 188.2m / Enterprise Value 3.20b)
FCF Margin = 6.79% (FCF TTM 188.2m / Revenue TTM 2.77b)
Net Margin = 9.88% (Net Income TTM 274.0m / Revenue TTM 2.77b)
Gross Margin = 66.56% ((Revenue TTM 2.77b - Cost of Revenue TTM 927.1m) / Revenue TTM)
Gross Margin QoQ = 67.38% (prev 65.49%)
Tobins Q-Ratio = 1.77 (Enterprise Value 3.20b / Total Assets 1.82b)
Interest Expense / Debt = 1.54% (Interest Expense 5.00m / Debt 325.6m)
Taxrate = 33.68% (41.8m / 124.0m)
NOPAT = 269.6m (EBIT 406.6m * (1 - 33.68%))
Current Ratio = 1.96 (Total Current Assets 842.2m / Total Current Liabilities 430.5m)
Debt / Equity = 0.31 (Debt 325.6m / totalStockholderEquity, last quarter 1.07b)
Debt / EBITDA = 0.39 (Net Debt 197.0m / EBITDA 505.9m)
Debt / FCF = 1.05 (Net Debt 197.0m / FCF TTM 188.2m)
Total Stockholder Equity = 1.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.93% (Net Income 274.0m / Total Assets 1.82b)
RoE = 27.38% (Net Income TTM 274.0m / Total Stockholder Equity 1.00b)
RoCE = 33.75% (EBIT 406.6m / Capital Employed (Equity 1.00b + L.T.Debt 203.9m))
RoIC = 21.52% (NOPAT 269.6m / Invested Capital 1.25b)
WACC = 5.61% (E(3.01b)/V(3.33b) * Re(6.11%) + D(325.6m)/V(3.33b) * Rd(1.54%) * (1-Tc(0.34)))
Discount Rate = 6.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.22%
[DCF Debug] Terminal Value 83.74% ; FCFF base≈144.5m ; Y1≈115.3m ; Y5≈77.7m
Fair Price DCF = 261.8 (EV 2.39b - Net Debt 197.0m = Equity 2.19b / Shares 8.38m; r=5.90% [WACC]; 5y FCF grow -24.16% → 2.90% )
EPS Correlation: -9.13 | EPS CAGR: -37.63% | SUE: 0.0 | # QB: 0
Revenue Correlation: 95.88 | Revenue CAGR: 23.89% | SUE: 1.06 | # QB: 1
EPS next Year (2026-12-31): EPS=20.70 | Chg30d=+0.049 | Revisions Net=+1 | Growth EPS=+11.2% | Growth Revenue=+5.2%